Welcome to the international HTA database

Showing [21959 Records] Selected Records [0 Hits] [Clear]

Year	Source	Title
2009	NIHR Health Technology Assessment programme	Trastuzumab for the treatment of primary breast cancer in HER2-positive women: a single technology appraisal
2010	National Institute for Health and Care Excellence (NICE)	Trastuzumab for the treatment of HER2-positive metastatic gastric cancer
2011	NIHR Health Technology Assessment programme	Trastuzumab for the treatment of HER2-positive metastatic adenocarcinoma of the stomach or gastro-oesophageal junction
2011	NIHR Health Technology Assessment programme	Trastuzumab for the treatment of HER2-positive metastatic adenocarcinoma of the stomach or gastro-oesophageal junction
2006	Quality Improvement Scotland (NHS QIS )	Trastuzumab for the adjuvant treatment of early-stage HER2-positive breast cancer
2006	National Institute for Health and Care Excellence (NICE)	Trastuzumab for the adjuvant treatment of early-stage HER2-positive breast cancer
2005	Institute for Clinical Effectiveness and Health Policy (IECS)	Trastuzumab for breast cancer treatment
2012	NIHR Horizon Scanning Centre (NIHR HSC)	Trastuzumab emtansine in combination with pertuzumab for HER2-positive metastatic breast cancer – first line
2013	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	Trastuzumab emtansine (KadcylaTM) for previously treated patients with HER2-positive advanced/metastatic breast cancer
2013	NIHR Horizon Scanning Centre (NIHR HSC)	Trastuzumab emtansine (Kadcyla) for patients with HER2 positive locally advanced or metastatic relapsed gastric cancers
2023	Agency for Care Effectiveness (ACE)	Trastuzumab deruxtecan for treating HER2-positive advanced gastric cancer after two or more therapies
2023	Agency for Care Effectiveness (ACE)	Trastuzumab deruxtecan for previously treated HER2-positive metastatic breast cancer
2005	NIHR Horizon Scanning Centre (NIHR HSC)	Trastuzumab as adjuvant therapy for early stage breast cancer - horizon scanning review
2003	ECRI	Trastuzumab [Herceptin (R)] for the treatment of breast cancer
2012	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Trastuzumab (Herceptin®) 150 mg powder for concentrate for solution for infusion
2012	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Trastuzumab (Herceptin®)
2006	NIHR Horizon Scanning Centre (NIHR HSC)	Trastuzumab (Herceptin) in combination with aromatase inhibitors for stage IV - metastatic breast cancer: horizon scanning technology briefing
2010	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	Trastuzumab (Herceptin) in addition to standard chemotherapy as first-line therapy for advanced gastric cancer
2007	HAYES, Inc.	Trastuzumab (Herceptin) for metastatic cancer
2001	The Swedish Council on Health Technology Assessment (SBU)	Trastuzumab (Herceptin) for metastasized breast cancer - early assessment briefs (Alert)
2010	NIHR Horizon Scanning Centre (NIHR HSC)	Trastuzumab (Herceptin) for HER2 positive early, locally advanced and inflammatory breast cancer - neoadjuvant treatment
2012	NIHR Horizon Scanning Centre (NIHR HSC)	Trastuzumab (Herceptin) for HER2 positive early breast cancer – two year regimen
2007	HAYES, Inc.	Trastuzumab (Herceptin) for early breast cancer
2007	NIHR Horizon Scanning Centre (NIHR HSC)	Trastuzumab (Herceptin) for advanced gastric cancer
2004	HAYES, Inc.	Trastuzumab (Herceptin (R)) for breast cancer
2016	NIHR Health Technology Assessment programme	TRAPEZE: a randomised controlled trial of the clinical effectiveness and cost-effectiveness of chemotherapy with zoledronic acid, strontium-89, or both, in men with bony metastatic castration-refractory prostate cancer
2011	HAYES, Inc.	Transvaginal ultrasound for measurement of cervical length to predict preterm birth
2003	National Institute for Clinical Excellence (NICE)	Transurethral radiofrequency needle ablation of the prostate
2007	HAYES, Inc.	Transurethral radiofrequency micro-remodeling using the Renessa system (Novasys Medical Inc.) for female stress urinary incontinence
2010	HAYES, Inc.	Transurethral Radiofrequency Micro-Remodeling Using the Renessa System (Novasys Medical Inc.) for Female Stress Urinary Incontinence
2001	HAYES, Inc.	Transurethral needle ablation therapy
2001	ECRI	Transurethral needle ablation [TUNA (R)] for benign prostatic hyperplasia
2005	Agencia de Evaluacion de Tecnologias Sanitarias (AETS)	Transurethral needle ablation (TUNA) in the treatment of symptomatic benign prostatic hyperplasia (BPH): a systematic review and meta-analysis
2002	Medical Services Advisory Committee (MSAC)	TransUrethral Needle Ablation (TUNA) for the treatment of benign prostatic hyperplasia
2000	Comite d'Evaluation et de Diffusion des Innovations Technologiques (CEDIT)	Transurethral microwave thermotherapy (TUMT) for benign prostatic hyperplasia
2000	HAYES, Inc.	Transurethral microwave thermotherapy
2007	HAYES, Inc.	Transurethral microwave thermotherapy
2012	Medical Services Advisory Committee (MSAC)	Transurethral injection of botulinum toxin into the ladder wall for urinary incontinence due to neurogenic detrusor overactivity
2003	National Institute for Clinical Excellence (NICE)	Transurethral electrovaporisation of the prostate
1994	Conseil d'Evaluation des Technologies de la Santé du Quebec (CETS)	Transurethral diathermy for benign prostatic hypertrophy: update -nonsystematic review
2013	HAYES, Inc.	Transradial, transbrachial, and transulnar approaches for coronary angiography and intervention
2011	Penn Medicine Center for Evidence-based Practice (CEP)	Transradial access for cardiac catheterization
2002	HAYES, Inc.	Transpupillary thermotherapy for choroidal tumors and macular degeneration
2002	NIHR Horizon Scanning Centre (NIHR HSC)	Transpupillary thermotherapy for age-related macular degeneration - horizon scanning review
2004	National Institute for Clinical Excellence (NICE)	Transpupillary thermotherapy for age-related macular degeneration
2003	Institute for Clinical Effectiveness and Health Policy (IECS)	Transpupillary thermotherapy
2007	New Zealand Health Technology Assessment (NZHTA)	Transportation of emergency patients
2012	NIHR Horizon Scanning Centre (NIHR HSC)	Transportable haemodialysis machines for established renal failure
2006	National Institute for Clinical Excellence (NICE)	Transport interventions promoting safe cycling and walking: evidence briefing
2002	Blue Cross Blue Shield Association (BCBS)	Transplanting adult patients with hematopoietic stem cells from placental and umbilical cord blood
1994	Healthcare Insurance Board/ College Voor Zorgverzekeringen (CVZ)	Transplantation with bone marrow not derived from HLA identical family donors for the treatment of adults and children with hemato-oncologic and congenital diseases - primary research
2001	The Swedish Council on Health Technology Assessment (SBU)	Transplantation of stem cells from umbilical cord blood - early assessment briefs (Alert)
2003	The Swedish Council on Health Technology Assessment (SBU)	Transplantation of cultured skin (Apligraf(R)) in treating venous leg ulcers - early assessment briefs (Alert)
2005	Technology Assessment Unit of the McGill University Health Centre (MUHC)	Transplantation of allogeneic hematopoietic stem cells from unrelated donors in adult patients at the MUHC
2002	HAYES, Inc.	Transperineal ultrasound-guided brachytherapy for early-stage prostate cancer
2010	National Institute for Health and Care Excellence (NICE)	Transperineal template biopsy of the prostate
2022	Norwegian Institute of Public Health (NIPH)	Transperineal compared with transrectal biopsy on suspected prostate cancer: a health technology assessment
2015	Canadian Agency for Drugs and Technologies in Health (CADTH)	Transoral robotic surgery: a review of clinical and cost-effectiveness
2017	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Transoral endoscopic thyroidectomy vestibular approach (TOETVA)
2002	Medical Services Advisory Committee (MSAC)	Transoesophageal echocardiography
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Transobturator slings for urinary incontinence: clinical effectiveness and guidelines
2005	National Institute for Clinical Excellence (NICE)	Transobturator foramen procedures for stress urinary incontinence
1998	Institute of Technology Assessment (ITA)	Transnational analysis of the socio-economic impact of Alzheimer's disease (AD) in the European Union
2011	Health Technology Assessment Section, Ministry of Health Malaysia (MaHTAS)	Transnasal oesophagoscopy (TNE)
1996	Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA)	Transmyocardial revascularization with laser
2002	Canadian Coordinating Office for Health Technology Assessment (CCOHTA)	Transmyocardial revascularization for treatment of angina
1998	University HealthSystem Consortium (UHC)	Transmyocardial revascularization
1998	Comite d'Evaluation et de Diffusion des Innovations Technologiques (CEDIT)	Transmyocardial revascularisation by laser (systematic review, expert panel)
2000	Institute for Clinical Systems Improvement (ICSI)	Transmyocardial laser therapy for severe refractory angina
2002	HAYES, Inc.	Transmyocardial laser revascularization
1999	Medical Services Advisory Committee (MSAC)	Transmyocardial laser revascularisation
2019	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Transmural fixation of aortic endograft adjunct to endovascular aneurysm repair using helical anchors
2020	Penn Medicine Center for Evidence-based Practice (CEP)	Transmission of respiratory infections via showers
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Transmission of infectious agents from magazines, books, and toys in healthcare settings: clinical evidence and guidelines
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Transmission of infectious agents and risk of injury from patient transfer boards in healthcare settings: clinical evidence
2003	L'Agence Nationale d'Accreditation d'Evaluation en Sante (ANAES)	Transluminal dilatation for symptomatic atheromatous stenosis of the carotid bifurcation
1995	NIHR Health Technology Assessment programme	Translation of Spanish report on routine pre-operative testing
2015	NIHR Health Services and Delivery Research programme	Translation into British Sign Language and validation of the Strengths and Difficulties Questionnaire
2018	Penn Medicine Center for Evidence-based Practice (CEP)	Transjugular Intrahepatic Portosystemic Shunts for Patients with Acute Variceal Bleeding
1996	Comite d'Evaluation et de Diffusion des Innovations Technologiques (CEDIT)	Transjugular intrahepatic porto-systemic shunt - systematic review, expert panel, primary research
2013	NIHR Health Services and Delivery Research programme	Transitions to palliative care for older people in acute hospitals: a mixed-methods study
2022	Agency for Healthcare Research and Quality (AHRQ)	Transitions of care from pediatric to adult services for children with special healthcare needs
2014	NIHR Health Services and Delivery Research programme	Transitions at the end of life for older adults - patient, carer and professional perspectives: a mixed-methods study
2014	Agency for Healthcare Research and Quality (AHRQ)	Transitional care interventions to prevent readmissions for people with heart failure
2011	Agency for Healthcare Research and Quality (AHRQ)	Transition of care for acute stroke and myocardial infarction patients: from hospitalization to rehabilitation, recovery, and secondary prevention
2014	Agency for Healthcare Research and Quality (AHRQ)	Transition care for children with special health needs
2004	National Institute for Clinical Excellence (NICE)	Transilluminated powered phlebectomy for varicose veins
2002	HAYES, Inc.	Transilluminated powered phlebectomy for symptomatic varicose veins
2013	Health Quality Ontario (HQO)	Transient ischemic attack: where can patients receive optimal care? A rapid review
2015	Health Quality Ontario (HQO)	Transient elastography for assessment of liver fibrosis and steatosis: OHTAC recommendation
2015	Health Quality Ontario (HQO)	Transient elastography for assessment of liver fibrosis and steatosis: an evidence-based analysis
2015	Health Quality Ontario (HQO)	Transient elastography and controlled attenuation parameter for diagnosing liver fibrosis and steatosis in Ontario: an economic analysis
2006	Canadian Agency for Drugs and Technologies in Health (CADTH)	Transient elastography (FibroScan) for non-invasive assessment of liver fibrosis
2008	NIHR Horizon Scanning Centre (NIHR HSC)	Transient elastography (FibroScan) for evaluating liver fibrosis
2004	Healthcare Insurance Board/ College Voor Zorgverzekeringen (CVZ)	Transhiatal oesophageal resection without thoracotomyversus transthoracic oesophageal resection with two-field lymph gland- primary research
2016	Penn Medicine Center for Evidence-based Practice (CEP)	Transfusion thresholds in cardiovascular surgery
2010	Penn Medicine Center for Evidence-based Practice (CEP)	Transfusion thresholds for orthopedic surgery patients
2010	Penn Medicine Center for Evidence-based Practice (CEP)	Transfusion thresholds for cardiovascular surgery patients
2005	Norwegian Knowledge Centre for the Health Services (NOKC)	Transfusion and alternative treatment in acute haemorrhage
2016	NIHR Health Services and Delivery Research programme	Transforming community health services for children and young people who are ill: a quasi-experimental evaluation